Search filters

Filters
Clear All

Phase

  • 3
  • 2
  • 4
  • 9
  • 1
  • 9

Found 9 abramson-cancer-center trials

A listing of abramson-cancer-center medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

 KEYMAKER-U02- substudy 02B

KEYMAKER-U02- substudy 02B

18-99 years
All genders
Phase 1
Patients from Penn Medicine's Abramson Cancer Center will be approached for participation.This sub-study is part of a larger research study that is testing experimental treatments for melanoma. Various study drugs will be tested in combination with pembrolizumab in this study. Treatment groups include: a) MK-7684 and pembrolizumab b) pembrolizumab alone …
 Tissue Collection for Multiple Myeloma Research

Tissue Collection for Multiple Myeloma Research

18-99 years
All genders
Interventional
The primary purpose of this research study is to obtain specimens (blood, bone marrow, and other tissues) for research about multiple myeloma and related diseases.
 EA2174: A Phase II/III Study of Peri-operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma

EA2174: A Phase II/III Study of Peri-operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma

18-99 years
All genders
Phase 3
This phase II/III trial studies the usefulness of treatment with nivolumab and ipilimumab in addition to standard of care chemotherapy and radiation therapy in patients with esophageal and gastroesophageal junction adenocarcinoma who are undergoing surgery. This trial is open to Penn Medicine's Abramson Cancer Center patients only. Please contact the …
 TACE Ax HCQ: Phase IB Study of Hepatic Chemoembolization Plus Axitinib and Hydrochlorquine for Liver-Dominant Metastatic Adenocarcinoma Of The Colon And Rectum

TACE Ax HCQ: Phase IB Study of Hepatic Chemoembolization Plus Axitinib and Hydrochlorquine for Liver-Dominant Metastatic Adenocarcinoma Of The Colon And Rectum

18-99 years
All genders
Phase 1
Interventional
Liver metastases are a leading cause of death among patients with metastatic colorectal cancer. Duration of disease control is short following 2nd-line or later systemic therapy. Liver-directed therapy such as TACE has a higher response rate and improves PFS, but the benefit is still limited. Cancer cells escape ischemic cell …
 UPCC 06717 / AMC 101: A Pilot Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas

UPCC 06717 / AMC 101: A Pilot Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas

18-64 years
All genders
Phase 1
Non-Hodgkin lymphoma  is a potentially curable condition with standard cancer treatment drugs (chemotherapy) and steroids. Standard lymphoma treatment includes chemotherapy, or cancer-fighting drugs, called etoposide, vincristine, cyclophosphamide, prednisone and doxorubicin (called EPOCH).  
 A071701 Genomically-Guided Treatment Trial in Brain Metastases

A071701 Genomically-Guided Treatment Trial in Brain Metastases

18-99 years
All genders
Interventional
This phase II trial studies how well genetic testing works in guiding treatment for patients with solid tumors that have spread to the brain. Several genes have been found to be altered or mutated in brain metastases such as NTRK, ROS1, CDK or PI3K. Medications that target these genes such …
 GMCI plus Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC Patients (LuTK02)

GMCI plus Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC Patients (LuTK02)

18-99 years
All genders
This trial is to evaluate the safety and efficacy of adding GMCI to standard of care in patients with stage III/IV NSCLC that are not responding to a first line immune checkpoint inhibitor (ICI).
 Managed Access Program (MAP) to provide access to CTL019  for acute lymphoblastic leukemia (ALL) or diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release

Managed Access Program (MAP) to provide access to CTL019 for acute lymphoblastic leukemia (ALL) or diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release

All genders
The purpose of this Treatment Plan is to allow access to tisagenlecleucel (CTL019) for eligible patients diagnosed with acute lymphoblastic leukemia (ALL) or large b-cell lymphomas who are unable to receive commercially manufactured product due to failure of the incoming apheresis material or outgoing product to meet the commercial specifications …
 Trial of ASP-1929 Photoimmunotherapy Versus Physician's Choice Standard of Care for the Treatment of Locoregional  Recurrent Head and Neck Squamous Cell Carcinoma

Trial of ASP-1929 Photoimmunotherapy Versus Physician's Choice Standard of Care for the Treatment of Locoregional Recurrent Head and Neck Squamous Cell Carcinoma

18-99 years
All genders
Phase 3
This is a Phase 3, randomized, double-arm, open-label trial of ASP-1929 photoimmunotherapy (ASP-1929 PIT) versus physician's choice standard of care (SOC) for the treatment of locoregional, recurrent head and neck squamous cell carcinoma (HNSCC) in patients who have failed or progressed on or after at least two lines of therapy, …